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dysplasia is associated with the development of immature 
vasculature 
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Background: Angiogenic squamous dysplasia (ASD) is a dysplastic 
lesion of the bronchial airways that is distinguished from other dys-
plasias by virtue of the presence of characteristic vascular morphology 
with projection of microvessels into the overlying dysplastic epithe-
lium. These lesions are associated with increased VEGF expression and 
high microvessel densities (MVD) in comparison to normal bronchial 
epithelium. In addition, we have recently demonstrated these lesions to 
be associated with longer periods of persistence in comparison to non-
ASD bronchial dysplasia. 
Methods: Immunohistochemical stains for CD31 and actin were 
performed on consecutive sections of bronchoscopically obtained 
biopsy material. CD31 and actin vessel densities for identical areas 
within each biopsy were produced by image analysis with collection 
of area measurements and vessel tags. A microvessel maturation index 
(MMI) was calculated via division of actin MVDs by CD31 MVDS 
for each biopsy. In addition, single vessel analyses were performed for 
microvessel papillary structures in ASD lesions.
Results: The mean MMI for twelve dysplastic lesions was signiﬁcantly 
less than that measured for four normal bronchial biopsies (MMI 0.62 
vs. 1.02, respectively; p=0.04). When analyzed independently, the 
vessels that project into the intraepithelial papillae of ASDs showed the 
lowest MMI of 0.56. This was not statistically different than the MMI 
for the dysplasia group as a whole but was signiﬁcantly decreased in 
comparison to normal MMI (p=0.71 and 0.04, respectively). Incom-
plete vascular maturation appears to be associated with dysplastic 
change in the bronchial airways and is most striking in the vascular 
structures of ASDs.
Conclusions: Angiogenesis in bronchial dysplasia is associated with 
reduced vascular maturation. Immature vasculature may have an 
impact on the growth and progression of dysplastic lesions. Increased 
delivery of pro-tumorigenic factors such as growth promoting factors 
and mutagenic substances may be facilitated by immature vascular net-
works. Further analysis of ASD associated vasculature may allow for 
the identiﬁcation of angiogenic mediators that control the maturation of 
microvessels in pre-neoplastic airway disease.
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Background: Alterations in genome structure (e.g. ampliﬁcations and 
deletions) have been identiﬁed as features of many types of cancer 
including lung cancer. A major challenge in the molecular study of lung 
cancer is the limited quantity of tumour tissue available from routine 
biopsy procedures. To address this challenge, whole genome ampliﬁca-
tion (WGA) methods utilizing Phi29 polymerase were developed to 
increase the amount of DNA available for analysis. The high sequence 
ﬁdelity of these techniques has been investigated using low resolution 
assays however the use of ampliﬁed material for copy number analysis 
has been questioned due to ampliﬁcation-induced bias. In this study, we 
investigate the use of ampliﬁed material for genome-wide copy number 
analysis of limited quantities of patient material.
Methods: Normal lymph nodes from three patients were fresh-frozen 
in OCT compound for tissue archival. DNA from these sources was 
extracted and 7ng (~1000 cell equivalents) subject to WGA using the 
QIAgen Repli-G Mini kit to generate over 10,000ng of product (~1.4M 
cell equivalents). To identify artifacts induced by the ampliﬁcation 
technique, pre- and post- ampliﬁcation samples were hybridized to the 
Affymetrix GeneChip Mapping 500k SNP and NimbleGen 384k CGH 
array platforms. Pre- and post- ampliﬁcation copy number comparisons 
were conducted to identify ampliﬁcation-induced copy number  
differences.
Results: Preliminary copy number analysis of the Affymetrix data from 
pre- and post-ampliﬁcation sample pairs has identiﬁed more than 700 
sites which were commonly over- or under-ampliﬁed. 63 of these sites, 
representing a maximum of 59Mb and often in telomeric regions, were 
under-ampliﬁed. 683 sites, representing a maximum of 685Mb and 
primarily in GC-rich regions, were commonly over-ampliﬁed.
Compensation for these reproducible biases can be achieved by com-
paring ampliﬁed samples to ampliﬁed samples. Preliminary pair-wise 
comparisons of ampliﬁed samples have shown recapitulation of copy 
number differences detected in corresponding unampliﬁed com-
parisons. In the example shown in Figure 1, the unampliﬁed (a) and 
ampliﬁed copy number comparison (c) identiﬁed 14 and 89 variants 
respectively. Both comparisons identiﬁed the relative increase in copy 
number marked by the arrow as the most signiﬁcant (p<0.0001).
Figure 1: Example of copy number detection using unamplified and amplified 
pair-wise comparisons
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Conclusions: Preliminary results suggest that Phi29-based whole 
genome ampliﬁcation introduces structural biases that may be related to 
the composition of the underlying DNA sequence. Some of the repro-
ducible biases induced by Phi29-based WGA may be compensated for 
by amplifying both samples in pair-wise copy number comparisons.
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Background: Adenocarcinoma is the most frequent histological sub-
types of lung cancers and atypical adenomatous hyperplasia (AAH) is 
considered as a preneoplastic lesion of adenocarcinoma. According to a 
hypothesis of multistep carcinogenesis, lung adenocarcinoma develops 
AAH to invasive adenocarcinoma through bronchioloalveolar carci-
noma (BAC). Noguchi classiﬁed small peripheral lung adenocarcinoma 
measured 2 cm or less in the greatest diameter into 6 types. Among 
them, type A, B and C have BAC components. EGFR mutations are 
frequently detected in never smokers and adenocarcinomas, especially 
those with BAC features. We investigate EGFR mutations, EGFR gene 
copy number, and KRAS mutations in AAH and Noguchi’s type A-C 
and analyzed the association among histological subsets and genetic 
and clinicopathological factors to clarify the role of genetic alterations 
on carcinogenesis of adenocarcinoma with BAC component.
Methods: Sixty lesions measured 2cm or less in greatest dimension 
which were obtained from 48 patients by surgery were studied: 4 AAH, 
19 Noguchi’s type A, 15 type B and 22 type C. EGFR mutations were 
examined using a mutant-enriched PCR assay for exon 19 deletions and 
L858R exon 21 mutation, and KRAS mutations were examined using 
a PCR assay for codon 12 point mutations. EGFR copy number was 
detected by a ﬂuorescence in situ hybridization (FISH) assay. 
Results: One lesion of AAHs had EGFR mutations (25%), but there 
were no KRAS mutations and high EGFR copy number status in 
AAHs. EGFR alterations had a tendency to increase the positive 
alteration according to the advance of histological classiﬁcation, and 
high EGFR copy number status was signiﬁcant frequently detected in 
Noguchi’s type C than AAH-B group including AAH, Noguchi’s type 
A and B in univariate analysis (Type C versus AAH-B: 31.8% versus 
5.3%, P=0.0091). KRAS mutations were detected in 5 lesions (8.3%) 
among total 60 lesions without statistical correlation with other factors. 
Multivariate analysis revealed that Noguchi’s type C signiﬁcantly cor-
related with larger tumor size (OR=3.61, 95%CI: 1.12-11.6, P=0.031) 
and high EGFR copy number status (OR=5.94, 95%CI: 1.25-28.3, 
P=0.025) than AAH-B group. 
Conclusions: EGFR mutations occur in the AAH lesion and may inﬂu-
ence the carcinogenesis of lung adenocarcinoma. By contrast, increased 
EGFR copy number may be a late event of tumor development and 
play a role in the progression of lung adenocarcinoma. 
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Background: KRAS codon 12 mutations occur in about 30% of 
non-small cell lung cancer (NSCLC) tissue and are associated with 
adenocarcinoma histology, poor survival and resistance to erlotinib or 
geﬁtinib. In this study, we evaluated the reliability and clinical signiﬁ-
cance of plasma KRAS mutations in NSCLC patients. 
Patients and Methods: 180 Swiss patients with NSCLC were screened 
for KRAS mutations in plasma and matched peripheral blood mono-
nuclear cells (PBMC) using a combined restriction fragment-length 
polymorphism and polymerase chain reaction (RFLP-PCR) assay. Sur-
vival analysis was performed using the Kaplan-Meier method and the 
Cox multivariate model. KRAS mutations were validated in a second 
laboratory by DNA sequencing, using matched plasma, serum, PBMC 
and tumor tissue. 
Results: Baseline characteristics: 69% male, 69% smokers, 86% stage 
IIIB/IV and 44% adenocarcinoma. Median age at diagnosis was 61 
years and median survival was 12 months. Chemotherapy was given 
to 78% of the patients, 27% had surgical resection and 12% radia-
tion. Mutation screening revealed KRAS mutations in 16/180 (9%) 
plasma and 0/180 (0%) PBMC samples. Plasma KRAS mutations (P 
= 0.014), tumor stage (P < 0.001) and surgical resection (P < 0.001) 
were independent predictors of prognosis in the multivariate model. 
No signiﬁcant associations were found between plasma KRAS muta-
tions and baseline characteristics or response to chemotherapy. DNA 
sequencing conﬁrmed circulating KRAS mutations in 11/15 evaluable 
cases. KRAS codon 12 sequences matched between blood and tumors 
in 7/9 evaluable cases. 
Conclusions: Plasma KRAS mutations were associated with poor 
survival and concordant with tumor KRAS mutations. Further studies 
are warranted to test if plasma KRAS mutations predict resistance to 
erlotinib or geﬁtinib in NSCLC patients. 
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Background: An increased copy number for the epidermal growth 
factor receptor (EGFR) gene has been suggested to be a valid marker to 
predict response of EGFR inhibitors in the advanced stage of lung can-
cer. However, no clear evidence has been demonstrated as to whether 
